Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP .
Applied Genetic Technologies CorporationMay 3, 2021 GMT
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021-
ALACHUA, Fla. and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced an encore presentation of previously reported data from the Company’s ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, Assistant Professor at Casey Eye Insti